The Complement System: An Intricate Pillar of Innate Immunity and Its Multifaceted Role in Health and Disease

Many thanks to our sponsor Esdebe who helped us prepare this research report.

Abstract

The complement system, a highly sophisticated and ancient component of the innate immune response, represents an intricate network of over 50 soluble and membrane-bound proteins. Its precise activation and regulation are fundamental to host defense, enabling the rapid detection and elimination of invading pathogens, removal of apoptotic and necrotic cellular debris, and clearance of immune complexes. This comprehensive report delves deeply into the molecular architecture and functional mechanisms of the complement cascade, meticulously detailing its three primary initiation pathways—the classical, alternative, and lectin pathways—and their convergence on a common terminal pathway culminating in the formation of the Membrane Attack Complex (MAC). Furthermore, it provides an exhaustive analysis of the numerous complement components, their cleaved fragments, and the sophisticated array of regulatory proteins that meticulously control complement activity to prevent collateral damage to host tissues. The report then critically examines the pervasive involvement of complement dysregulation in a wide spectrum of human pathologies, ranging from autoimmune and inflammatory disorders to infectious diseases, various renal conditions, neurodegenerative disorders, and even cancer, underscoring its dual capacity as both a protective shield and a driver of disease. Finally, it explores the burgeoning field of complement-targeted therapeutics, highlighting current and emerging strategies that harness our understanding of this complex system for clinical intervention.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction: The Guardian of Immune Homeostasis

The complement system, derived from the Latin ‘complementum’ meaning ‘that which completes or makes perfect’, was initially recognized in the late 19th century for its ability to ‘complement’ the antibody-mediated killing of bacteria. Far from merely assisting antibodies, it is now understood as a crucial, independent, and highly dynamic arm of the innate immune system, capable of initiating rapid and robust defense mechanisms. Comprising a complex array of serum proteins, cell-surface receptors, and regulatory molecules, the complement system serves as a first line of defense against microbial threats and plays a critical role in maintaining tissue homeostasis. It acts as an immediate effector system, bridging the gap between innate and adaptive immunity through various intricate feedback loops and crosstalk mechanisms.

Circulating in the bloodstream, lymph, and extracellular fluids in an inactive pro-enzyme form, complement proteins are poised for rapid activation upon encountering specific triggers. This activation typically involves a cascade of sequential proteolytic cleavages, where one activated component cleaves the next, leading to an amplified response. The primary functions elicited by complement activation include:

• Opsonization: The coating of pathogens or cellular debris with complement fragments (e.g., C3b, iC3b) marking them for efficient phagocytosis by immune cells possessing complement receptors.
• Chemotaxis and Inflammation: The generation of potent anaphylatoxins (C3a, C4a, C5a) that recruit and activate immune cells, induce mast cell degranulation, increase vascular permeability, and promote local inflammation.
• Direct Lysis of Target Cells: The formation of the Membrane Attack Complex (MAC) on the surface of pathogens, leading to the creation of pores and osmotic lysis.
• Immune Complex Clearance: The binding of complement components to antigen-antibody complexes, facilitating their transport and removal by phagocytic cells, thereby preventing their harmful deposition in tissues.
• Modulation of Adaptive Immunity: Influence on B cell activation, T cell responses, and dendritic cell maturation and antigen presentation.

The complement system operates through three principal activation pathways: the classical, alternative, and lectin pathways. While each pathway has a distinct initiation mechanism, they converge at the point of C3 activation, leading to the formation of C3 convertases, which are central to the cascade. Subsequent steps involve the formation of C5 convertases and the assembly of the terminal MAC, representing the common effector arm of the system. The exquisite balance between robust activation and stringent regulation is paramount to prevent uncontrolled complement activity and consequential damage to host tissues.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Activation Pathways: Orchestrating Immune Defense

The complement system’s remarkable efficiency lies in its ability to be activated rapidly and specifically through three distinct, yet interconnected, pathways:

2.1. The Classical Pathway: Antibody-Initiated Defense

The classical pathway is primarily initiated by the binding of antibodies to antigens, forming immune complexes, although it can also be activated by certain pathogen surfaces directly (e.g., C-reactive protein binding to phosphorylcholine on bacterial surfaces, or direct binding to viral particles and apoptotic cells). The most potent activators are pentameric immunoglobulin M (IgM) and certain subclasses of immunoglobulin G (IgG), specifically IgG1, IgG2, and IgG3. IgM, due to its pentameric structure, can effectively bind multiple antigenic sites and provide a stable platform for complement activation, requiring only a single molecule to initiate the cascade. In contrast, IgG typically requires at least two IgG molecules in close proximity on an antigenic surface to effectively bind and activate complement.

The initiation phase of the classical pathway centers around the C1 complex, a macromolecular assembly composed of three distinct subcomponents: one molecule of C1q, two molecules of C1r, and two molecules of C1s (C1qr2s2). C1q is a fascinating molecule with a ‘bouquet of tulips’ structure, featuring six globular heads attached to collagen-like stalks. These globular heads are responsible for recognizing and binding to the Fc (fragment crystallizable) regions of antibodies within immune complexes or directly to certain non-antibody activators (e.g., C-reactive protein, bacterial lipopolysaccharides, apoptotic cell surfaces).

Upon binding to its target, C1q undergoes a conformational change that triggers the auto-activation of the associated C1r serine proteases. Activated C1r (C1r) then cleaves the inactive C1s zymogens into active C1s (C1s). This activated C1s* is the crucial enzyme responsible for the proteolytic cleavage of the next two components in the cascade: C4 and C2.

1. C4 Cleavage: C1s* cleaves C4 into two fragments: C4a (a small anaphylatoxin) and C4b. C4b is highly reactive due to an exposed thioester bond. If it does not covalently attach to a nearby surface (e.g., the pathogen surface or an immune complex) within microseconds, it is rapidly hydrolyzed and inactivated. Surface-bound C4b serves as a binding site for C2.
2. C2 Cleavage: C2 binds to surface-bound C4b. C1s* then cleaves C2 into C2a and C2b (note: in older literature, C2a was sometimes referred to as C2b and vice versa; current nomenclature dictates C2a is the smaller fragment, C2b the larger catalytic fragment). The larger fragment, C2b, remains associated with C4b, forming the C4b2b complex. This complex is the classical pathway C3 convertase.

The C3 convertase (C4b2b) is the pivotal enzyme at this stage, responsible for cleaving numerous molecules of C3. Each C3 molecule is cleaved into C3a (a potent anaphylatoxin) and C3b. Similar to C4b, C3b also contains a highly reactive thioester bond, enabling it to covalently attach to nearby surfaces, including the pathogen itself, or the C4b2b complex. The deposition of C3b on the pathogen surface is crucial for opsonization.

Some C3b molecules bind to the pre-existing C4b2b C3 convertase, forming a trimolecular complex: C4b2b3b. This new complex is the classical pathway C5 convertase. The formation of the C5 convertase marks the transition from the amplification loop to the terminal pathway.

2.2. The Alternative Pathway: Spontaneous and Amplified Defense

The alternative pathway is a unique and ancient pathway, capable of continuous low-level ‘tick-over’ activation in the plasma, even in the absence of an immune challenge. This inherent activity provides an immediate, antibody-independent defense mechanism. It also serves as a critical amplification loop for both the classical and lectin pathways once C3b is generated.

The ‘tick-over’ mechanism begins with the spontaneous hydrolysis of the thioester bond in circulating C3, forming C3(H2O) (also sometimes called C3b-like C3). This conformationally altered C3(H2O) is capable of binding Factor B, another serum protein. Once bound, Factor B becomes susceptible to cleavage by Factor D, a constitutively active serine protease that circulates in its active form.

1. Factor B Cleavage: Factor D cleaves Factor B into two fragments: Ba (a small fragment) and Bb (the larger fragment containing the catalytic site). The Bb fragment remains associated with C3(H2O), forming the fluid-phase C3 convertase, C3(H2O)Bb.
2. Fluid-Phase C3 Convertase Activity: C3(H2O)Bb cleaves additional C3 molecules into C3a and C3b. Most of the C3b generated in the fluid phase is rapidly inactivated due to hydrolysis or regulatory proteins. However, a small proportion of C3b molecules can covalently attach to nearby surfaces.

Crucially, the fate of surface-bound C3b determines whether the alternative pathway continues to amplify or is shut down. Host cell surfaces are typically protected by an array of regulatory proteins that rapidly inactivate C3b. In contrast, pathogen surfaces (e.g., bacterial cell walls, fungal cell walls, viral envelopes, certain parasites) often lack these regulatory proteins, or their structures actively promote C3b stabilization.

When C3b lands on an unprotected surface (e.g., a pathogen), it can bind Factor B. This surface-bound C3b-Factor B complex is then cleaved by Factor D, generating C3bBb. This complex, C3bBb, is the alternative pathway C3 convertase. Its activity is significantly enhanced and stabilized by Properdin (Factor P), a positive regulator that binds to and extends the half-life of the C3bBb convertase on the surface from a few minutes to up to 30 minutes, allowing for substantial amplification.

This surface-bound C3bBb convertase then cleaves more C3 molecules into C3a and C3b, creating an amplification loop where newly generated C3b can initiate further C3bBb formation. This positive feedback loop ensures a rapid and robust deposition of C3b on the pathogen surface.

Finally, some of the newly generated C3b molecules bind to existing C3bBb complexes, forming a trimolecular complex: C3bBbC3b. This is the alternative pathway C5 convertase, which then proceeds to cleave C5 and initiate the terminal pathway.

2.3. The Lectin Pathway: Pattern Recognition for Immediate Response

The lectin pathway, a relatively recently discovered pathway, functions as a crucial bridge between innate pattern recognition and complement activation. It is initiated when specific soluble pattern recognition receptors (PRRs) in the serum, known as collectins and ficolins, bind to conserved carbohydrate patterns found on the surface of various microorganisms (e.g., mannose, N-acetylglucosamine, fucose, glucose) that are typically absent or inaccessible on host cells.

Key initiators of the lectin pathway include:

• Mannose-binding Lectin (MBL): An oligomeric protein that recognizes and binds to mannose and N-acetylglucosamine residues on pathogen surfaces. MBL is structurally similar to C1q, possessing multiple carbohydrate-recognition domains.
• Ficolins: A family of proteins (L-ficolin, H-ficolin, M-ficolin) that recognize N-acetylglucosamine and other carbohydrate patterns. Like MBL, ficolins associate with MASPs.

Upon binding to target carbohydrates, MBL or ficolins undergo a conformational change that activates associated serine proteases, known as MBL-associated serine proteases (MASPs). The most critical MASPs for complement activation are MASP-1 and MASP-2. MASP-3 also exists but primarily plays a role in the alternative pathway amplification through Factor D activation.

1. MASP Activation: When MBL or ficolins bind to their ligands, they activate MASP-1 and MASP-2. While MASP-1 can cleave C2 and C3 directly, its primary role is thought to be in activating MASP-2.
2. C4 and C2 Cleavage: Activated MASP-2 then cleaves C4 into C4a and C4b, and C2 into C2a and C2b. As in the classical pathway, C4b covalently attaches to the surface, and C2b associates with it to form the C4b2b complex.

Similar to the classical pathway, the C4b2b complex generated by the lectin pathway serves as the C3 convertase, cleaving C3 into C3a and C3b. Subsequent steps are identical to the classical pathway: C3b acts as an opsonin and can bind to the C3 convertase to form the C5 convertase (C4b2b3b), which then initiates the terminal pathway.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. The Terminal Pathway: Membrane Attack Complex Formation

All three activation pathways converge at the cleavage of C5, leading to the formation of the Membrane Attack Complex (MAC), also known as C5b-9. This common terminal pathway is the primary mechanism by which the complement system directly lyses target cells, including bacteria, fungi, parasites, and even infected host cells.

1. C5 Cleavage: The C5 convertase (C4b2b3b from the classical/lectin pathways, or C3bBbC3b from the alternative pathway) cleaves C5 into two fragments: C5a and C5b. C5a is a potent anaphylatoxin and chemotactic factor, playing a significant role in inflammation (discussed in detail later).
2. C5b Initiation: C5b, similar to C3b and C4b, is highly unstable in solution. If it is to initiate MAC formation, it must rapidly bind to the target cell membrane or remain associated with the C5 convertase on the surface. Once bound, C5b undergoes conformational changes that expose binding sites for subsequent components.
3. Sequential Assembly (C6, C7, C8): C6 then binds to membrane-bound C5b. This C5b6 complex then binds C7, leading to a hydrophobic change in C7 that allows it to insert into the lipid bilayer of the target cell membrane. Next, C8 binds to the C5b67 complex. C8 is a trimeric protein (C8α, C8β, C8γ). The C8α-γ subunit also inserts into the membrane, and critically, the C8α subunit creates a small pore (approximately 10 Å in diameter) in the target cell membrane.
4. C9 Polymerization: The pre-pore complex (C5b678) acts as a template for the binding and polymerization of multiple (typically 10-18) molecules of C9. C9, structurally similar to perforin, polymerizes to form a large, transmembrane pore (approximately 100 Å in diameter). These pores disrupt the osmotic integrity of the cell membrane, leading to an influx of water and ions, eventually causing cell swelling and osmotic lysis.

The formation of these pores on the pathogen membrane leads to rapid depolarization, disruption of cellular processes, and ultimately, cell death. While effective against certain bacteria (e.g., Neisseria species), many Gram-negative bacteria have evolved mechanisms to resist MAC insertion or repair membrane damage.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Complement Components and Their Diverse Functions

The complement system is a highly organized ensemble of proteins, each contributing specific enzymatic, structural, or regulatory roles. These components are typically designated with a ‘C’ followed by a number (C1-C9) or by a letter (e.g., Factor B, Factor D, Properdin). Cleaved fragments are denoted by ‘a’ (smaller fragment, often released) or ‘b’ (larger fragment, often remains bound or becomes active).

• C1 Complex (C1q, C1r, C1s): The initiating complex of the classical pathway. C1q is the recognition subunit, binding to immune complexes or certain pathogen surfaces. C1r and C1s are serine proteases; C1r activates C1s, and C1s cleaves C4 and C2.
• C4: Cleaved by C1s (classical pathway) or MASP-2 (lectin pathway) into C4a and C4b. C4b is a reactive fragment that covalently attaches to surfaces and forms part of the C3 convertase (C4b2b) and C5 convertase (C4b2b3b). C4a is an anaphylatoxin.
• C2: Cleaved by C1s (classical pathway) or MASP-2 (lectin pathway) into C2a and C2b. C2b is the larger catalytic fragment that associates with C4b to form the C3 convertase (C4b2b). C2a is a small kinin-like fragment whose physiological role is less defined.
• C3: The central and most abundant complement protein, serving as the fulcrum of all three pathways. Cleaved by C3 convertases into C3a and C3b. C3b is a critical opsonin, promoting phagocytosis, and also participates in the formation of C5 convertases (C4b2b3b and C3bBbC3b). C3a is a potent anaphylatoxin.
• C5: Cleaved by C5 convertases into C5a and C5b. C5a is the most potent anaphylatoxin and a powerful chemoattractant for phagocytes. C5b initiates the assembly of the Membrane Attack Complex (MAC).
• C6, C7, C8, C9: These components sequentially assemble with C5b to form the MAC. C6 and C7 bind to C5b, followed by the insertion of C7 into the membrane. C8 then binds and inserts, creating a small pore. Multiple C9 molecules polymerize to form the larger, definitive transmembrane pore, leading to osmotic lysis.
• Factor B (FB): A serum protein that binds to C3(H2O) or C3b in the alternative pathway. It is cleaved by Factor D into Ba and Bb. Bb is the catalytic subunit of the alternative pathway C3 convertase (C3bBb) and C5 convertase (C3bBbC3b).
• Factor D (FD): A constitutively active serine protease in the plasma that cleaves Factor B. It is unique in that it circulates in its active form.
• Properdin (Factor P): The only known positive regulator of the complement system. It stabilizes the alternative pathway C3 convertase (C3bBb) and C5 convertase (C3bBbC3b) on surfaces, extending their half-life and amplifying the alternative pathway response.
• Mannose-binding Lectin (MBL) and Ficolins: Soluble pattern recognition molecules that initiate the lectin pathway by binding to specific carbohydrate patterns on pathogen surfaces.
• MBL-associated Serine Proteases (MASP-1, MASP-2, MASP-3): Serine proteases associated with MBL and ficolins. MASP-2 is the primary enzyme responsible for cleaving C4 and C2 in the lectin pathway. MASP-1 is involved in MASP-2 activation and can also cleave C3 and Factor B. MASP-3 is involved in the alternative pathway amplification loop by activating Factor D and Factor B.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Regulatory Mechanisms: Safeguarding Host Tissues

The tremendous destructive potential of the complement system necessitates an exquisitely tight regulatory network to prevent indiscriminate activation and self-damage to host tissues. This regulation occurs at multiple levels, involving both soluble plasma proteins and membrane-bound proteins expressed on host cells. These regulators function by inhibiting convertase formation, accelerating convertase decay, cleaving active components, or preventing MAC assembly.

5.1. Fluid-Phase Regulators

• C1 Inhibitor (C1-INH): A crucial serine protease inhibitor (serpin) that regulates the classical and lectin pathways. C1-INH irreversibly binds to and inactivates activated C1r and C1s, as well as MASP-1 and MASP-2, thereby preventing their cleavage of C4 and C2. It also regulates the contact activation system and fibrinolysis. Deficiency or dysfunction of C1-INH leads to Hereditary Angioedema (HAE).
• C4b-binding Protein (C4BP): A major soluble regulator of the classical and lectin pathways. C4BP binds to C4b, acting as a cofactor for Factor I-mediated cleavage of C4b, effectively inactivating it. It also accelerates the decay of the classical and lectin pathway C3 convertase (C4b2b).
• Factor H (FH): The principal soluble regulator of the alternative pathway. Factor H binds to C3b, acting as a cofactor for Factor I-mediated cleavage and inactivation of C3b (iC3b). It also competes with Factor B for binding to C3b and accelerates the decay of the alternative pathway C3 convertase (C3bBb). Factor H specifically recognizes host cell surfaces due to its affinity for polyanionic structures (e.g., sialic acids, glycosaminoglycans), ensuring that the alternative pathway is preferentially regulated on host cells.
• Factor I (FI): A serine protease that, in conjunction with its cofactors (Factor H, C4BP, MCP, CR1), irreversibly cleaves and inactivates C3b into iC3b, C3c, and C3dg, and C4b into iC4b. Factor I deficiency leads to uncontrolled complement activation and C3 consumption.
• S-Protein (Vitronectin) and Clusterin: These soluble proteins prevent the insertion of the C5b67 complex into cell membranes and inhibit the polymerization of C9, thereby blocking MAC formation in the fluid phase. They are particularly important in preventing spontaneous MAC formation in plasma.

5.2. Membrane-Bound Regulators

Host cell membranes are protected by several integral membrane proteins that specifically inactivate complement components deposited on their surfaces.

• Decay-Accelerating Factor (DAF, CD55): A glycosylphosphatidylinositol (GPI)-anchored protein expressed on most cell types. DAF accelerates the decay (dissociation) of both classical/lectin pathway C3 convertase (C4b2b) and alternative pathway C3 convertase (C3bBb), thereby preventing further C3 cleavage.
• Membrane Cofactor Protein (MCP, CD46): A widely expressed transmembrane protein that acts as a cofactor for Factor I, facilitating the cleavage and inactivation of C3b and C4b on host cell surfaces. MCP is particularly important in protecting self-cells from complement attack.
• Complement Receptor 1 (CR1, CD35): Expressed primarily on erythrocytes, phagocytes, B cells, and some T cells. CR1 functions as a cofactor for Factor I-mediated cleavage of C3b and C4b, and also accelerates the decay of both C3 and C5 convertases. Its role on erythrocytes is critical for transporting C3b- and C4b-coated immune complexes to the liver and spleen for clearance.
• Protectin (CD59): A GPI-anchored protein widely expressed on host cells. CD59 binds to the C5b-8 complex, preventing the binding and polymerization of C9 molecules and thus inhibiting the final assembly of the MAC. This is a critical last-line defense against self-lysis.

The intricate interplay of these activators and regulators ensures that the complement system effectively targets and eliminates threats while preserving the integrity of host tissues. Dysregulation of these control mechanisms is a hallmark of many complement-mediated diseases.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Biological Functions of Complement: Beyond Pathogen Lysis

While direct cell lysis is a well-known outcome, the complement system exerts a much broader influence on immune responses and tissue homeostasis through its various fragments and receptors.

6.1. Opsonization and Phagocytosis

The deposition of C3b and its inactive derivative, iC3b, on the surface of pathogens and apoptotic cells is a critical function known as opsonization. Phagocytic cells, such as macrophages and neutrophils, express various complement receptors (CRs) on their surface, including CR1 (CD35), CR3 (CD11b/CD18), and CR4 (CD11c/CD18), which bind to C3b and iC3b. This binding significantly enhances the efficiency of phagocytosis, allowing immune cells to internalize and destroy opsonized targets much more effectively than non-opsonized ones. This process is vital for the clearance of bacteria, fungi, and immune complexes.

6.2. Anaphylatoxic and Chemotactic Activity

The small cleavage fragments C3a, C4a, and C5a are collectively known as anaphylatoxins due to their ability to induce mast cell degranulation, leading to the release of histamine and other inflammatory mediators. These mediators cause:

• Increased Vascular Permeability: Facilitating the extravasation of fluid, plasma proteins, and immune cells into inflamed tissues.
• Smooth Muscle Contraction: Contributing to bronchospasm (e.g., in asthma) and gut motility.

Of these, C5a is the most potent anaphylatoxin and a powerful chemoattractant. It acts through specific receptors (C5aR1/CD88 and C5aR2/C5L2) on myeloid cells (neutrophils, macrophages, monocytes) and other cell types. C5a orchestrates the recruitment of phagocytes to sites of infection and inflammation, enhances their adhesive properties, and primes them for increased cytokine production, oxidative burst, and degranulation. C3a also has chemotactic properties, albeit less potent than C5a.

6.3. Immune Complex Clearance

The complement system plays a crucial role in preventing the pathological deposition of immune complexes (ICs) in tissues. C3b and C4b bind to ICs in the bloodstream. Erythrocytes, which express high levels of CR1 (CD35), bind these C3b/C4b-coated ICs. The erythrocytes then transport these ICs to the liver and spleen, where they are stripped from the red blood cells by resident macrophages and safely cleared. Deficiencies in complement components (e.g., C1, C4, C2) or CR1 can lead to impaired IC clearance, contributing to autoimmune diseases like Systemic Lupus Erythematosus (SLE) due to the accumulation and deposition of ICs in tissues, triggering chronic inflammation.

6.4. Link to Adaptive Immunity

The complement system is not merely a standalone innate defense but profoundly influences and interacts with the adaptive immune response.

• B Cell Activation: Complement fragments, particularly C3d (a breakdown product of C3b that remains covalently bound to antigens), can bind to B cell co-receptors (CD21/CD19/CD81 complex). This co-ligation with the B cell receptor (BCR) significantly lowers the threshold for B cell activation, promoting antibody production and affinity maturation. This mechanism allows for more robust and specific antibody responses, especially to T-dependent antigens.
• Antigen Presentation: C3b and iC3b can bind to antigens, facilitating their uptake by antigen-presenting cells (APCs) such as dendritic cells and macrophages via complement receptors. This enhances antigen processing and presentation to T cells, thereby influencing T cell activation and differentiation.
• Germinal Center Formation: Complement components are crucial for the proper formation and maintenance of germinal centers within lymphoid organs, where B cells undergo proliferation, somatic hypermutation, and class switching to generate high-affinity antibodies.

6.5. Clearance of Apoptotic Cells and Tissue Homeostasis

The complement system contributes significantly to the maintenance of tissue homeostasis by facilitating the orderly removal of apoptotic and necrotic cells. C1q and MBL can directly bind to exposed molecules on the surface of apoptotic cells (e.g., phosphatidylserine, DNA, histones), initiating complement activation, primarily the classical and lectin pathways. The subsequent deposition of C3b and iC3b on these cells labels them for efficient, non-inflammatory engulfment by phagocytes. This timely clearance prevents the release of potentially autoimmunogenic intracellular contents that could trigger inflammatory responses and autoimmunity.

Moreover, complement components are increasingly recognized for their roles in tissue repair, regeneration, angiogenesis, and even neurodevelopment, indicating functions far beyond mere immune defense.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Complement System in Human Diseases: A Double-Edged Sword

While essential for host defense, dysregulation of the complement system—whether due to genetic deficiencies, overactivation, or inadequate regulation—is implicated in the pathogenesis of a vast array of human diseases. Its dual nature makes it a target for both protective immunity and destructive pathological processes.

7.1. Autoimmune Disorders

Abnormal complement activation or impaired complement regulation is a hallmark of many autoimmune conditions.

• Systemic Lupus Erythematosus (SLE): Deficiencies in early classical pathway components (C1q, C4, C2) are strongly associated with SLE. These deficiencies impair the clearance of immune complexes and apoptotic cells, leading to their accumulation and deposition in tissues like the kidneys, joints, and skin. This triggers chronic inflammation and tissue damage, perpetuating the autoimmune cycle. Conversely, overactivation of complement by lupus autoantibodies (e.g., anti-dsDNA antibodies) can directly contribute to tissue injury (e.g., lupus nephritis) through MAC formation and C3a/C5a-mediated inflammation.
• Rheumatoid Arthritis (RA): Complement activation, particularly through the classical and alternative pathways, contributes significantly to the synovial inflammation and joint destruction characteristic of RA. Immune complexes (e.g., rheumatoid factor-IgG complexes) activate complement in the synovial fluid, leading to the generation of C3a and C5a, which attract and activate inflammatory cells, and C5b-9, which contributes to cartilage degradation.
• Antiphospholipid Syndrome (APS): A thrombotic and obstetric autoimmune disorder. Anti-β2-glycoprotein I antibodies, when bound to phospholipid-binding proteins, can activate the complement system (primarily the classical pathway), leading to C5a-mediated inflammation and thrombosis, as well as placental damage in pregnancy complications.
• Myasthenia Gravis (MG): Autoantibodies against the acetylcholine receptor (AChR) at the neuromuscular junction activate the classical complement pathway. This leads to MAC formation and destruction of the postsynaptic membrane, impairing neuromuscular transmission and causing muscle weakness.
• Neuromyelitis Optica Spectrum Disorder (NMOSD): Autoantibodies against aquaporin-4 (AQP4-IgG) activate the classical pathway in the central nervous system, leading to astrocyte injury, demyelination, and neuronal damage through MAC deposition and C5a-mediated inflammation.
• Pemphigus Vulgaris/Foliaceus: Autoantibodies against desmoglein adhesion molecules activate complement at the dermal-epidermal junction, leading to acantholysis (loss of cell-cell adhesion) and blistering.

7.2. Inflammatory Conditions and Tissue Injury

Excessive or uncontrolled complement activation is a major driver of inflammation and tissue damage in various non-autoimmune conditions.

• Atherosclerosis: Complement components (C1q, C3, MAC) are found within atherosclerotic plaques. Complement activation, particularly the alternative pathway, contributes to endothelial dysfunction, foam cell formation, smooth muscle cell proliferation, and plaque rupture. C3a and C5a promote inflammation within the vessel wall.
• Ischemia-Reperfusion Injury (IRI): Occurs after temporary blood flow interruption to an organ (e.g., heart attack, stroke, organ transplantation) followed by restoration of flow. The reintroduction of oxygen and nutrients paradoxically triggers massive complement activation (classical, alternative, and lectin pathways), leading to significant tissue damage via MAC formation and anaphylatoxin-mediated inflammation. This is a major cause of organ damage post-transplantation.
• Age-related Macular Degeneration (AMD): The leading cause of blindness in the elderly. Genetic variations in complement genes, particularly Factor H (FH), are strongly associated with AMD. Impaired regulation by FH leads to chronic, low-grade complement activation and inflammation in the retina, contributing to the formation of drusen (deposits under the retina) and subsequent retinal degeneration.
• Inflammatory Bowel Disease (IBD): Complement activation is observed in the inflamed gut mucosa of patients with Crohn’s disease and ulcerative colitis. Anaphylatoxins C3a and C5a contribute to mucosal inflammation, epithelial barrier dysfunction, and tissue damage.
• Asthma: Complement components, especially C3a and C5a, are elevated in asthmatic airways and contribute to airway hyperresponsiveness, bronchoconstriction, and inflammatory cell recruitment.
• Sepsis: A life-threatening systemic inflammatory response to infection. Uncontrolled and systemic complement activation during sepsis contributes to widespread endothelial damage, organ dysfunction, and coagulopathy, often leading to multiple organ failure.

7.3. Infectious Diseases

Complement plays a critical protective role against infections, and deficiencies increase susceptibility. However, pathogens have also evolved sophisticated mechanisms to evade or even exploit the complement system.

• Bacterial Infections: Deficiencies in terminal pathway components (C5-C9) significantly increase susceptibility to recurrent, systemic infections by Neisseria species (N. meningitidis, N. gonorrhoeae), which are highly sensitive to MAC-mediated lysis. Deficiencies in C3 or earlier components (C1, C4, C2) lead to broader susceptibility to encapsulated bacteria like Streptococcus pneumoniae and Haemophilus influenzae, due to impaired opsonization and phagocytosis. Pathogens also express complement evasion proteins, such as Factor H binding proteins, C4BP binding proteins, and proteases that cleave complement components.
• Viral Infections: Viruses employ numerous strategies to evade complement, including expressing complement regulatory proteins similar to host regulators, or by degrading complement components. Conversely, complement can contribute to viral pathogenesis (e.g., in Dengue fever, HIV) or enhance antiviral immunity. For SARS-CoV-2 (COVID-19), complement activation, particularly the lectin and alternative pathways, is strongly implicated in lung injury, thrombosis, and systemic inflammation in severe cases, potentially contributing to immunothrombosis and ARDS (Acute Respiratory Distress Syndrome Syndrome).
• Fungal and Parasitic Infections: Complement is crucial for defense against many fungi and parasites, primarily through opsonization and direct lysis. Deficiencies in C3 or Factor B, for instance, predispose to candidiasis.

7.4. Renal Diseases

The kidney is particularly vulnerable to complement-mediated damage, leading to a spectrum of debilitating renal disorders.

• Atypical Hemolytic Uremic Syndrome (aHUS): A rare, life-threatening genetic disorder characterized by uncontrolled alternative pathway activation, leading to microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It is often caused by mutations in genes encoding alternative pathway regulators (e.g., Factor H, Factor I, MCP) or gain-of-function mutations in Factor B or C3.
• C3 Glomerulopathy (C3G) and Dense Deposit Disease (DDD): A group of rare kidney diseases characterized by predominant C3 deposition in the glomeruli. They result from dysregulation of the alternative pathway, often due to autoantibodies (e.g., C3 Nephritic Factor stabilizing C3 convertase) or genetic defects in complement regulators or components, leading to excessive C3 activation and glomerular damage.
• Membranoproliferative Glomerulonephritis (MPGN): Often associated with uncontrolled complement activation, particularly in MPGN Type II (now classified as DDD) and some cases of MPGN Type I.

7.5. Neurological Disorders

Emerging evidence highlights the role of complement in neuroinflammation and neurodegeneration.

• Alzheimer’s Disease (AD): Complement components (C1q, C3, C4, MAC) are found co-localized with amyloid plaques and neurofibrillary tangles. C1q can directly bind to aggregated amyloid-beta. Chronic activation of the classical pathway is thought to contribute to synaptic loss and neuronal damage. Complement also plays a physiological role in synaptic pruning during development, but dysregulated pruning in AD could contribute to pathology.
• Parkinson’s Disease (PD): Complement components are present in Lewy bodies (alpha-synuclein aggregates). Complement activation may contribute to dopaminergic neuronal death and neuroinflammation.
• Multiple Sclerosis (MS): Complement is involved in demyelination. Autoantibodies targeting myelin can activate the classical pathway, leading to MAC formation and destruction of oligodendrocytes and myelin sheaths.
• Stroke: Similar to IRI, complement activation contributes to brain tissue damage following ischemic or hemorrhagic stroke, exacerbating neuronal death.

7.6. Cancer

The role of complement in cancer is complex and often described as a ‘double-edged sword’.

• Anti-tumor immunity: Complement can directly lyse tumor cells via MAC, opsonize tumor cells for phagocytosis, and enhance anti-tumor adaptive immunity. C1q can recognize apoptotic tumor cells, and certain chemotherapies induce tumor cell apoptosis that sensitizes them to complement-mediated killing.
• Pro-tumorigenic effects: Chronic, low-level complement activation in the tumor microenvironment can promote tumor growth, angiogenesis, metastasis, and immune evasion. C3a and C5a can act as growth factors for tumor cells, induce immunosuppressive cells (e.g., myeloid-derived suppressor cells), and promote an inflammatory, pro-tumorigenic milieu. MAC formation can also induce non-lytic signals that promote cell survival and proliferation.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Therapeutic Implications: Targeting Complement for Disease Modulation

Given its pivotal role in numerous diseases, the complement system has emerged as a highly attractive target for therapeutic intervention. The goal is to selectively inhibit pathological complement activity while preserving its protective functions.

8.1. Current Therapies

Several complement-targeting drugs have gained regulatory approval, revolutionizing the treatment of previously intractable conditions:

• Eculizumab (Soliris): The first complement inhibitor approved, it is a humanized monoclonal antibody that binds to C5, preventing its cleavage into C5a and C5b. By blocking C5 cleavage, it effectively inhibits both MAC formation and the generation of the potent anaphylatoxin C5a. Eculizumab is approved for Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), generalized Myasthenia Gravis (gMG), and Neuromyelitis Optica Spectrum Disorder (NMOSD). Its success has validated complement as a therapeutic target.
• Ravulizumab (Ultomiris): A second-generation C5 inhibitor designed with a longer half-life than eculizumab, allowing for less frequent dosing (every 8 weeks versus every 2 weeks). It offers a more convenient treatment regimen for PNH and aHUS.
• C1-INH Concentrates (e.g., Berinert, Cinryze, Ruconest, Takhzyro (lanadelumab)): Used for Hereditary Angioedema (HAE). These therapies replace or augment the deficient C1-INH, thereby controlling the classical pathway and contact system overactivation that leads to angioedema attacks. Lanadelumab is a monoclonal antibody that inhibits plasma kallikrein, an enzyme upstream of C1-INH’s primary targets, offering an alternative prophylactic approach for HAE.

8.2. Emerging Therapies and Future Directions

Building on the success of C5 inhibition, research is actively exploring new targets within the complement cascade to offer more precise or broader therapeutic effects, or to address conditions not responsive to C5 blockade.

• C3 Inhibition: As C3 is central to all three pathways, inhibiting C3 offers the potential for broad complement suppression. Pegcetacoplan (Empaveli), a C3 inhibitor, has been approved for PNH, offering an alternative to C5 inhibitors and potentially addressing extravascular hemolysis. Other C3-targeted approaches are in development for AMD and C3 glomerulopathy.
• Factor B Inhibition: Inhibitors of Factor B target the alternative pathway, offering a selective blockade. Iptacopan (oral Factor B inhibitor) is in clinical trials for PNH and C3G. Danicopan is another Factor B inhibitor.
• Factor D Inhibition: Factor D is essential for alternative pathway activation. Inhibitors of Factor D, such as avacopan (Tavneos), an oral C5aR1 antagonist, indirectly reduce alternative pathway activation. While technically a C5a receptor antagonist, its clinical efficacy in ANCA-associated vasculitis demonstrates the benefit of targeting complement downstream of C3. Direct Factor D inhibitors are also in development for dry AMD.
• C1s Inhibition: Targeting C1s specifically inhibits the classical pathway, leaving the alternative and lectin pathways intact. Sutimlimab (Enjaymo), a C1s inhibitor, is approved for cold agglutinin disease, an autoimmune hemolytic anemia where classical pathway activation drives red blood cell destruction.
• MASP-2 Inhibition: Inhibitors of MASP-2 selectively block the lectin pathway, which is implicated in conditions like ischemia-repurfusion injury. Narsoplimab (Omeros OMIDRIA), an anti-MASP-2 antibody, has shown promise in preventing IRI after kidney transplantation.
• C5a/C5aR Inhibition: Blocking C5a or its receptor (C5aR1) can mitigate the inflammatory effects of complement without necessarily preventing MAC formation. Avacopan (mentioned above) is a prominent example. Other C5aR1 antagonists are in trials for various inflammatory and autoimmune conditions, as well as sepsis and COVID-19-related inflammation.
• Dual Targeting and Combination Therapies: Future strategies may involve targeting multiple points in the cascade or combining complement inhibitors with other immunomodulatory drugs to achieve optimal therapeutic outcomes and minimize side effects.

Challenges in complement therapeutics include the risk of increased susceptibility to infections (especially meningococcal infections for C5 inhibitors), the need for precise targeting to avoid systemic immunosuppression, and the complexities of delivering inhibitors to specific tissues.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

9. Conclusion

The complement system, with its intricate network of activation pathways, components, and regulatory mechanisms, stands as a cornerstone of innate immunity and a vital link to adaptive responses. Its capacity for rapid, amplified action is indispensable for host defense against a myriad of pathogens and for maintaining cellular and tissue homeostasis through the efficient clearance of immune complexes and apoptotic debris. However, this potent system, when dysregulated by genetic predispositions, acquired factors, or persistent triggers, becomes a formidable contributor to the pathogenesis of a wide spectrum of human diseases.

From debilitating autoimmune conditions like SLE and rheumatoid arthritis, to life-threatening inflammatory syndromes such as sepsis and ischemia-reperfusion injury, and specialized disorders impacting the kidney, eye, and central nervous system, complement’s multifaceted involvement underscores its significance in clinical medicine. The growing understanding of its precise molecular mechanisms has paved the way for groundbreaking therapeutic interventions, exemplified by the success of C5 and C1-INH inhibitors, which have transformed the management of previously untreatable diseases. The current therapeutic landscape is rapidly evolving, with a pipeline of novel inhibitors targeting different points of the cascade, promising more tailored and effective treatments. Further research into the nuanced biology of complement, particularly its non-canonical roles in health and disease, holds immense potential for uncovering new therapeutic targets and refining existing strategies, ultimately advancing patient care across diverse medical disciplines. The complement system remains a dynamic and fascinating area of immunological research, continually revealing its pervasive and often surprising influence on human physiology and pathology.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

• Walport, M. J. (2001). Complement. New England Journal of Medicine, 344(14), 1058-1066.
• Merle, N. S., Church, S. E., Fremeaux-Bacchi, L. & Roumenina, L. T. (2015). Complement system part I: molecular mechanisms of activation and regulation. Frontiers in Immunology, 6, 262.
• Merle, N. S., Noël, L. H., Roumenina, L. T., Dragon-Durey, M. A. & Fremeaux-Bacchi, L. (2015). Complement system part II: role in immunity. Frontiers in Immunology, 6, 257.
• Ricklin, D., Hajishengallis, G., Yang, K. & Lambris, J. D. (2010). Complement: a key system for immune surveillance and homeostasis. Nature Immunology, 11(9), 789-797.
• Sarma, J. V., & Ward, P. A. (2011). The C5a anaphylatoxin and the C5a receptors. Molecular Immunology, 48(7), 1000-1007.
• Morgan, B. P. (2009). Complement Membrane Attack. Sub-cellular Biochemistry, 49, 137-161.
• Zipfel, P. F., Skerka, C., & Hellwage, J. (2007). Complement and diseases: genetic and molecular aspects. Annual Review of Genomics and Human Genetics, 8, 307-331.
• Holers, V. M. (2019). The spectrum of complement abnormalities in rheumatic diseases. Nature Reviews Rheumatology, 15(7), 416-427.
• Ricklin, D., Quigg, R. J., & Lambris, J. D. (2013). Complement in renal disease: a fresh perspective. Immunological Reviews, 252(1), 183-194.
• Wagner, E., & Madelung, A. (2020). Complement as a therapeutic target in neurological disorders. Journal of Neuroinflammation, 17(1), 1-13.
• Afzali, B., & Bajwa, G. (2022). Complement in COVID-19: Implications for Therapeutics and Biomarkers. Kidney International Reports, 7(6), 1147-1150.
• Markiewski, M. M., & Lambris, J. D. (2007). The role of complement in cancer. Nature Reviews Cancer, 7(12), 923-932.
• Jury, E. C., & Ciurtin, C. (2021). The role of complement in rheumatoid arthritis. Frontiers in Immunology, 12, 705881.
• Morgan, B. P. (2000). Regulation of the membrane attack pathway. Immunopharmacology, 46(2), 125-142.
• Mastellos, D. C., & Lambris, J. D. (2020). Complement therapeutics in the 21st century: a new dawn. Nature Reviews Drug Discovery, 19(3), 195-212.
• Kolev, M., & Kemper, C. (2018). Complement’s terminal pathway and MAC: molecular insights and therapeutic implications. Immunological Reviews, 282(1), 133-146.
• Prodeus, A. P., Goellner, J., Sang, H., Thornton, B. P., & Frank, M. M. (1998). A critical role for complement in the development of antigen-specific B cells. Immunity, 9(5), 721-731.